The U.S. digital therapeutics market would grow at a CAGR of 24.85% over the predicted time frame. The market is expected to increase in value from US$ 2.05 Bn in 2022 to US$ 12.09 Bn in 2030.
The on U.S. digital therapeutics Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.
Download Free Sample@ https://www.precedenceresearch.com/sample/2410
A recent report provides crucial insights along with application based and forecast information in the Global U.S. digital therapeutics Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the U.S. digital therapeutics market.
A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.
Companies and Manufacturers Covered
The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global U.S. digital therapeutics market are included as given below:
U.S. digital therapeutics Market Key Players
- Omada Health Inc.
- 2Morrow Inc.
- Teladoc Health, Inc
- Pear Therapeutics (U.S), Inc.
- Fitbit Health Solutions
- Welldoc, Inc
- Click Therapeutics
- Noom, Inc.
- Akili, Inc.
- Better Therapeutics, Inc
Market Segments
By Application
- Diabetes
- Obesity
- Central Nervous System Diseases
- Cardiovascular Disease (CVD)
- Respiratory Disease
- Smoking Cessation
- Gastrointestinal Disorder (GID)
- Others
By Product
- Software
- Device
By End Use
- Patients
- Providers
- Payers
- Employers
- Others
Report Objectives
- To define, describe, and forecast the global U.S. digital therapeutics market based on product, and region
- To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
- To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
- To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
- To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the U.S. digital therapeutics market
Table of Content
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on U.S. Digital Therapeutics Market
5.1. COVID-19 Landscape: U.S. Digital Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global U.S. Digital Therapeutics Market, By Application
8.1. U.S. Digital Therapeutics Market, by Application, 2022-2030
8.1.1 Diabetes
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Obesity
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Central Nervous System Diseases
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Cardiovascular Disease (CVD)
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Respiratory Disease
8.1.5.1. Market Revenue and Forecast (2017-2030)
8.1.6. Smoking Cessation
8.1.6.1. Market Revenue and Forecast (2017-2030)
8.1.7. Gastrointestinal Disorder (GID)
8.1.7.1. Market Revenue and Forecast (2017-2030)
8.1.8. Others
8.1.8.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global U.S. Digital Therapeutics Market, By Product
9.1. U.S. Digital Therapeutics Market, by Product, 2022-2030
9.1.1. Software
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Device
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global U.S. Digital Therapeutics Market, By End Use
10.1. U.S. Digital Therapeutics Market, by End Use, 2022-2030
10.1.1. Patients
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Providers
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Payers
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Employers
10.1.4.1. Market Revenue and Forecast (2017-2030)
10.1.5. Others
10.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global U.S. Digital Therapeutics Market, Regional Estimates and Trend Forecast
11.1. U.S.
11.1.1. Market Revenue and Forecast, by Application (2017-2030)
11.1.2. Market Revenue and Forecast, by Product (2017-2030)
11.1.3. Market Revenue and Forecast, by End Use (2017-2030)
Chapter 12. Company Profiles
12.1. Omada Health Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. 2Morrow Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Teladoc Health, Inc
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Pear Therapeutics (U.S), Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Fitbit Health Solutions
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Welldoc, Inc
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Click Therapeutics
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Noom, Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Akili, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Better Therapeutics, Inc
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
0 Comments